Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention

Wada, Hideki; Dohi, Tomotaka; Miyauchi, Katsumi; Shitara, Jun; Endo, Hirohisa; Naito, Ryo; Konishi, Hirokazu; Tsuboi, Shuta; Ogita, Manabu; Kasai, Takatoshi; Hassan, Ahmed; Okazaki, Shinya; Isoda, Kikuo; Shimada, Kazunori; Suwa, Satoru; Daida, Hiroyuki

doi:10.1253/circj.cj-16-0790

Cited by 28 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings may be associated with the medications used by both groups (C and S) since all patients use oral hypoglycemic agents (metformin and glibenclamide) and statins. Studies show that metformin, glibenclamide, and statins reduce the production of the inflammatory cytokine IL-1 β and CRP and the expression of TNF- α [59–61]. …”

Section: Discussionmentioning

confidence: 99%

Lycium barbarumReduces Abdominal Fat and Improves Lipid Profile and Antioxidant Status in Patients with Metabolic Syndrome

Zanchet

Nardi

Bratti

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Natural antioxidants present in fruits have attracted considerable interest due to their presumed safety and potential nutritional value. Even though antioxidant activities of many fruits have been reported, the effects of phytochemicals of goji berry (GB) in patients with metabolic syndrome have not been investigated. In this study, we examined anthropometric and biochemical parameters in patients with metabolic syndrome after the consumption of GB. The patients were divided into two groups, control (C) and supplemented (S), and followed up for 45 days. Participants were individually instructed to carry out a healthy diet, but additionally, an inclusion of 14 g of the natural form of goji berry in the diet during 45 days for the S group was proposed. After 45 days of study, a significant reduction in transaminases as well as an improvement in lipid profile in the S group was observed. Likewise, a significant reduction in the waist circumference of the S group was observed when compared with that of the C group, and increased glutathione and catalase levels associated with a reduction of lipid peroxidation. These results suggest that this is an effective dietary supplement for the prevention of cardiovascular diseases in individuals with metabolic syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Lycium barbarumReduces Abdominal Fat and Improves Lipid Profile and Antioxidant Status in Patients with Metabolic Syndrome

Zanchet

Nardi

Bratti

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Indeed, in our PCI registry, the median preprocedural hs-CRP level in patients who underwent PCIs was significantly higher in patients with CKD (0.13 mg/dL) than in those without CKD (0.09 mg/dL; P < 0.001). 16) However, the present study is the first to show the clinical significance of inflammation in patients with preliminary diagnoses of CKD and non-CKD.…”

Section: Discussionmentioning

confidence: 71%

Clinical Significance of High-Sensitivity C-Reactive Protein in Patients with Preserved Renal Function Following Percutaneous Coronary Intervention

et al. 2019

Self Cite

View full text Add to dashboard Cite

Although high-sensitivity C-reactive protein (hs-CRP) has been used to predict the risk of adverse cardiac events in patients with coronary artery disease (CAD) after percutaneous coronary interventions (PCIs), little is known about the association between hs-CRP and long-term outcomes in patients with preserved renal function.Here, we studied 1,153 patients with stable CAD and preserved renal function (estimated glomerular filtration rate: > 60 mL/minute/1.73 m 2 ) who underwent their first PCI between 2000 and 2011. Those with available data on preprocedural hs-CRP were included. Patients were assigned to tertiles according to preprocedural hs-CRP levels. The incidence of major adverse cardiac events (MACE), including all-cause death and nonfatal myocardial infarction, was evaluated. During a median follow-up period of 7.5 years, Kaplan-Meier curves showed ongoing divergence in the rates of MACE among the hs-CRP tertiles (hs-CRP < 0.05 mg/L, 12.1%; 0.05-0.17 mg/L, 12.1%; > 0.17 mg/L, 21.6%; log-rank P = 0.003). After adjusting for the established cardiovascular risk factors, hs-CRP levels were found to be associated with a higher incidence of MACE (hazard ratio [HR]: 3.65, 95% confidence interval [CI]: 1.77-7.07; P = 0.0008) and a higher rate of all-cause mortality (HR: 5.14, 95% CI: 2.38-10.30; P < 0.0001).In conclusion, this long-term registry showed that preprocedural hs-CRP measurement is clinically useful for long-term risk assessments in patients with stable CAD and preserved renal function.(Int Heart J 2019; 60: 1037-1042)

show abstract

“…Other studies [32][33][34] also reported that elevated CRP levels reflect MACE in patients with ACS. Some reports [35,36] defined MACEs as pure coronary events such as target vessel revascularization, MI, and in-stent restenosis. However, our study included all causes of death such as HF as MACEs.…”

Section: Discussionmentioning

confidence: 99%

Thrombomodulin can predict the incidence of second events in patients with acute coronary syndrome: Single-center, retrospective cohort study

Kosaki

Minoura

Ogura

et al. 2018

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention

Cited by 28 publications

References 31 publications

Lycium barbarumReduces Abdominal Fat and Improves Lipid Profile and Antioxidant Status in Patients with Metabolic Syndrome

Lycium barbarumReduces Abdominal Fat and Improves Lipid Profile and Antioxidant Status in Patients with Metabolic Syndrome

Clinical Significance of High-Sensitivity C-Reactive Protein in Patients with Preserved Renal Function Following Percutaneous Coronary Intervention

Thrombomodulin can predict the incidence of second events in patients with acute coronary syndrome: Single-center, retrospective cohort study

Contact Info

Product

Resources

About